VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active CD.

Inclusion Criteria:Men or women, 18 to 75 years of age, inclusive, at the time of consentCapable of giving signed informed consentDocumented diagnosis of CD ≥ 3 months prior to Day 1. The diagnosis of CD must be confirmed by clinical, endoscopic, and histologic evidence.Moderately to severely active CDExclusion Criteria:Current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, or infectious colitisPresence of a stoma or ileoanal pouchPresence of currently known complications of CD such as fulminant colitis, toxic megacolon or any other manifestation that may require surgery or hospitalizationKnown diagnosis of short gut or bowel syndromePrevious exposure to VTX958 or any other TYK2 inhibitor (eg, deucravacitinib) in any study